- Pacgen Biopharmaceuticals Contracts Vancouver-based Syreon Corporation for its Phase I/II Clinical Trials of PAC-113 Mouthrinse in HIV Seropositive Patients with Oral Candidiasis
Pacgen Biopharmaceuticals Contracts Vancouver-based Syreon Corporation for its Phase I/II Clinical Trials of PAC-113 Mouthrinse in HIV Seropositive Patients with Oral Candidiasis
Vancouver, BC, Canada, October 24, 2005 –Pacgen Biopharmaceuticals Corporation has contracted Syreon Corporation to provide comprehensive clinical trial services for its phase I/II clinical trials of its PAC-113 investigational mouth rinse for the treatment of oral candidiasis.
Under the terms of the contract, Syreon will provide project management, clinical data management, biostatistical analysis and medical writing services. Syreon will subcontract onsite monitoring to ASKA Research, a Division of Valerie Willetts and Associates Inc., also based in Vancouver.
Pacgen is an international biotechnology company specializing in the development of innovative peptide therapeutics for the prevention and treatment of infectious diseases and immune system regulations where current therapeutics are inadequate or ineffective.
The product under development by Pacgen is a mouthrinse formulation, containing a novel active ingredient, PAC-113, which is a 12 amino-acid antimicrobial peptide that has demonstrated a high level of in vitro activity against Candida albicans, including drug-resistant HIV patient isolates.
A phase I/II clinical trial in HIV patients with oral candidiasis is ready to begin with three notable USA universities. PAC-113 is protected with composition of matter and use patents worldwide.
Pacgen’s Director of Drug Development Jasmina Markov stated “We chose Syreon for this trial due to the strategic and cost advantages of working with an established locally-based Canadian CRO”.
“Syreon is pleased to be selected by Pacgen to provide the services needed for this trial and is committed to working as a true partner to ensure its smooth operation from development through to close out” said Cindy Trytten, Vice President of Syreon Corporation.
Syreon is Vancouver's largest contract research organization specializing in clinical data management, including electronic data capture and online reporting. Founded in 1994 by Dr. Paul Keown, Professor of Medicine at UBC, Syreon provides clinical research services for evaluation of new medicines in phase I clinical development through to global phase IV multicentre trials of marketed products.
Contact: Jasmina Markov